Show Stocks and Investing Publications • Mon, May 15, 2023
Alec Stranahan Maintained (YMAB) at Hold with Increased Target to $12 on, May 15th, 2023
an-maintained-ymab-at-hold-with-increased-target-to-12-on-may-15th-2023.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIAlec Stranahan of B of A Securities, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Hold with Increased Target from $6 to $12 on, May 15th, 2023.
Alec has made no other calls on YMAB in the last 4 months.
There are 6 other peers that have a rating on YMAB. Out of the 6 peers that are also analyzing YMAB, 1 agrees with Alec's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Etzer Darout of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, April 3rd, 2023
These are the ratings of the 5 analyists that currently disagree with Alec
- David Nierengarten of "Wedbush" Upgraded from Hold to Buy and Increased Target to $13 on, Wednesday, May 10th, 2023
- Michael Ulz of "Morgan Stanley" Maintained at Sell with Increased Target to $7 on, Wednesday, May 10th, 2023
- William Plovanic of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $21 on, Tuesday, May 9th, 2023
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $11 on, Tuesday, April 4th, 2023
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $18 on, Friday, March 31st, 2023
Like: 👍